Omada Health makes managing chronic conditions easier by supporting members between doctors' visits.

Members are paired with the health coach empowered by insights from smart devices and AI-powered

tools. Learn more at OmataHealth.com. Omada Health is proudly NASDAQ listed.

From the opinion pages of the Wall Street Journal, this is Potomac Watch.

A top health official exits the FDA after the agency puts a hold on shipments of a gene therapy for muscular dystrophy and then reverses itself after a public outcry.

Meantime, health secretary Robert F. Kennedy Jr. says he's going to overhaul the National

Vaccine Injury Compensation Program to make it easier for claimants and their trial lawyers

to get payouts.

Welcome, I'm Kyle Peterson with the Wall Street Journal.

We are joined today by my colleagues, editorial board

member Kate Batchelder O'Dell, and columnist Alicia Finley. Vinay Prasad has been the chief

regulator for vaccines and biologics since being appointed to the agency in May, but he is now

out of the agency as of Tuesday, a government spokesman saying

this, Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration

and has decided to return to California and spend more time with his family, unquote. But some of the

press reports are suggesting that he was ousted and made controversies at the

agency. One of these involves a gene therapy for dushan muscular dystrophy. The company says that about

a thousand patients have been treated with it, but after two deaths, the FDA moved this month to halt

deliveries. And then on Monday, it seemed to have a change of heart.

Let's start with a clip of FDA Commissioner Marty McCarrie,

discussing this on CNBC.

That was a very temporary hold on the ambulatory population,

...